Vivanco Hidalgo, Rosa MaríaGomez, AlejandraMoreira Villanueva, AntíaDíez, LauraElosua Llanos, RobertoRoquer, Jaume2017-11-272017-11-272016Vivanco-Hidalgo RM, Gomez A, Moreira A, Díez L, Elosua R, Roquer J. Prevalence of cardiovascular risk factors in people with epilepsy. Brain Behav. 2016 Dec 20;7(2):e00618. DOI: 10.1002/brb3.6182162-3279http://hdl.handle.net/10230/33337OBJECTIVES: Epilepsy has been associated with cardiovascular comorbidity. This study aimed to assess the potential association between cardiovascular risk factors (CRFs), antiepileptic drugs (AEDs), and etiology. MATERIAL AND METHODS: A single-center retrospective epilepsy cohort from the decade of 2004-2013 was assessed. Poisson regression models with robust variance were estimated to obtain CRF prevalence ratios (PR) according to AED prescription and etiology. RESULTS: After excluding patients in the monotherapy group with vascular etiology or previous cardiovascular events, in the remaining 400 patients, enzyme-inducer AEDs (EIAEDs), especially phenytoin (PHT), were associated with higher prevalence of dyslipidemia (PRa 1.77, p < .05), compared to valproic acid. No etiology was associated with higher prevalence of any CRF. CONCLUSIONS: Patients treated with EIAEDs, especially PHT, had higher prevalence of dyslipidemia.application/pdfengCopyright © 2016 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. This is an open access article under the terms of the https://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.EpilèpsiaCor -- Malaltiesinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1002/brb3.618Antiepileptic drugsCardiovascular risk factorsComorbidityEpilepsyinfo:eu-repo/semantics/openAccess